PT  - JOURNAL ARTICLE
AU  - Hutchinson, Anna M
AU  - Chen, Wei-Min
AU  - Onengut-Gumuscu, Suna
AU  - Benitez-Aguirre, Paul
AU  - Cameron, Fergus J
AU  - Chiesa, Scott T
AU  - Couper, Jennifer J
AU  - Craig, Maria E
AU  - Dalton, Neil R.
AU  - Daneman, Denis
AU  - Davis, Elizabeth A
AU  - Deanfield, John E
AU  - Donaghue, Kim C
AU  - Jones, Timothy W
AU  - Mahmud, Farid H
AU  - Marshall, Sally M
AU  - Neil, Andrew
AU  - Rich, Stephen S
AU  - Marcovecchio, M. Loredana
AU  - Wallace, Chris
TI  - Genome-wide association study of longitudinal urinary albumin excretion in patients with type 1 diabetes
AID  - 10.1101/2022.12.19.22283443
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.19.22283443
4099  - http://medrxiv.org/content/early/2022/12/19/2022.12.19.22283443.short
4100  - http://medrxiv.org/content/early/2022/12/19/2022.12.19.22283443.full
AB  - Identifying genetic determinants for longitudinal changes in albumin excretion in individuals with type 1 diabetes may help identify those that are predisposed to renal, retinal and cardiovascular complications. Most studies have focussed on genetic predisposition to diabetic kidney disease and used cross-sectional measurements of urinary albumin excretion, but with limited success. Here, we utilise the wealth of longitudinal data and bio-samples collected from cohorts of childhood-onset type 1 diabetes followed over the last 30 years to describe a novel trajectory phenotype quantifying urinary albumin excretion changes during childhood and adolescence. We conducted a genome-wide association study and fine-mapping analysis for albumin excretion in 1584 individuals, finding one signal for cross-sectional albumin excretion close to GALNTL6 (rs150766792), which validated in a previous independent study, and a novel genome-wide significant signal for albumin excretion trajectory in the CDH18 gene region (rs145715205). Our trajectory phenotype quantifies albumin progression and offers a complementary measure to an albumin excretion phenotype based on a single measurement (i.e. most recent data collection) or an average of repeated measurements in longitudinal studies. It can be used to identify genetic or other risk factors which predict better or worse prognosis, thus facilitating the development of new preventive and therapeutic approaches.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAH is funded by the Engineering and Physical Sciences Research Council (EPSRC; EP/R511870/1) and the Medical Research Council (MRC; MC UU 00002/4). CW is funded by the Wellcome Trust (WT220788), the Medical Research Council (MRC; MC UU 00002/4), GSK and MSD and supported by the NIHR Cambridge BRC (BRC-1215-20014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This research was funded in whole, or in part, by the Wellcome Trust (WT220788). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The AdDIT study was funded by Diabetes UK, Juvenile Diabetes Research Foundation, the British Heart Foundation and in Canada the JDRF-Canadian Clinical Trial Network (CCTN), the Canadian Diabetes Association and the Heart and Stroke Foundation Canada. The Oxford Regional Prospective Study was funded by Diabetes UK. The NFS is funded by the Juvenile Diabetes Research Foundation, the Wellcome Trust and Diabetes UK. We acknowledge the study field workers, paediatricians, physicians, and diabetes nurse specialists involved in the ORPS/NFS/AdDIT studies and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. The funding for the genotyping and Q/C for the JDRF Diabetic Nephropathy Collaborative Research Initiative was through JDRF grant #17-2013-7.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:GWAS summary statistics will be made publicly available on the GWAS Catalog. Code to perform the analysis is available via https://github.com/annahutch/T1D-ACR and https://github.com/chr1swallace/acr-p-values. Phenotype data is available upon request.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors